FIELD: chemistry.
SUBSTANCE: present invention relates to an antibody, in particular to a monoclonal antibody which is capable of binding to IGF-1R. Invention also relates to a murine hybridoma, as well as to an antibody-drug conjugate for treating cancer.
EFFECT: invention widens the range of antibodies capable of binding with IGF-1R.
20 cl, 33 dwg, 16 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY AND MEDICINAL AGENT CONJUGATE AND USE THEREOF FOR TREATING CANCER | 2015 |
|
RU2685259C2 |
| CONJUGATE OF ANTI-IGF-1R ANTIBODY WITH DRUG AND USE THEREOF FOR TREATING CANCER | 2015 |
|
RU2692563C2 |
| COMPOSITION FOR TREATING IGF-1R EXPRESSING CANCER | 2016 |
|
RU2728568C2 |
| PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALIN XCD3, EPCAMXCD3, IGF-1RXCD3 OR FAP-ALPHA XCD3 BISPECIFIC SINGLE-CHAIN ANTIBODY WITH INTER-SPECIES SPECIFICITY | 2009 |
|
RU2547600C2 |
| ANTI-CXCR4 ANTIBODIES AND USING THEM FOR TREATING CANCER | 2009 |
|
RU2573897C2 |
| CSF-1R ANTIBODY | 2009 |
|
RU2547586C2 |
| BISPECIFIC ANTIBODIES | 2011 |
|
RU2573588C2 |
| METHODS OF TREATING CHRONIC PAIN | 2009 |
|
RU2522493C2 |
| NEW ANTIBODIES INHIBITING C-MET DIMERISATION AND USING THEM | 2008 |
|
RU2552161C2 |
| IGF-1R ANTIBODY AND USE THEREOF FOR DIAGNOSING CANCER | 2016 |
|
RU2706967C2 |
